## 历史时间线 - **1991** 在特拉华创立 - **1990s-2000s** 建立激酶抑制剂研究平台 - **2011** Jakafi获批治疗骨髓纤维化 - **2017** 与诺华合作开发CAR-T细胞疗法 - **2020** Jakafi获批治疗慢性移植物抗宿主病 - **2023** 收入约35亿美元
This listing is from the official public ClawHub registry. Review SKILL.md and referenced scripts before running.
Install skill "incyte-corp" with this command: npx skills add hanxueyuan/incyte-corp
核心收入来自Jakafi（ruxolitinib）——JAK1/2抑制剂。管线聚焦肿瘤学（PD-1/PD-L1组合疗法）和炎症（特应性皮炎）。
Jakafi在骨髓纤维化领域几乎是垄断地位——首个获批的JAK抑制剂。激酶抑制剂平台可扩展到其他靶点。
Incyte最初是一家为其他制药公司提供激酶筛选服务的公司——他们建立了全球最大的激酶化合物库之一。
This detail page is rendered from real SKILL.md content. Trust labels are metadata-based hints, not a safety guarantee.
Related by shared tags or category signals.
Design pipes-and-filters for sequential data transformations
Select optimal information sources for tool calls and file reads, balancing accuracy with token efficiency
Surface expert frameworks and methodologies
Configure pre-commit hooks for linting, type checking, formatting, and testing to enforce quality gates on every commit